Cargando…
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib
Although lactate dehydrogenase (LDH) serum levels, indirect markers of angiogenesis, are associated with a worse outcome in several tumours, their prognostic value is not defined in pancreatic cancer. Moreover, high levels are associated even with a lack of efficacy of tyrosine kinase inhibitors, co...
Autores principales: | Faloppi, Luca, Bianconi, Maristella, Giampieri, Riccardo, Sobrero, Alberto, Labianca, Roberto, Ferrari, Daris, Barni, Sandro, Aitini, Enrico, Zaniboni, Alberto, Boni, Corrado, Caprioni, Francesco, Mosconi, Stefania, Fanello, Silvia, Berardi, Rossana, Bittoni, Alessandro, Andrikou, Kalliopi, Cinquini, Michela, Torri, Valter, Scartozzi, Mario, Cascinu, Stefano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741511/ https://www.ncbi.nlm.nih.gov/pubmed/26397228 |
Ejemplares similares
-
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New
por: Faloppi, Luca, et al.
Publicado: (2016) -
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis
por: Bittoni, Alessandro, et al.
Publicado: (2015) -
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
por: Bianconi, Maristella, et al.
Publicado: (2016) -
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management
por: Del Prete, Michela, et al.
Publicado: (2015) -
Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach
por: Bittoni, Alessandro, et al.
Publicado: (2013)